Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma

Min Kang, Fangfang Wang, Xueyin Liao, Pingting Zhou, Rensheng Wang, Min Kang, Fangfang Wang, Xueyin Liao, Pingting Zhou, Rensheng Wang

Abstract

The present study is to compare the efficacy and adverse effects of intensity-modulated radiotherapy (IMRT) combined with endostar and IMRT combined with concurrent chemotherapy on locally advanced nasopharyngeal carcinoma (NPC).A total of 23 patients with stage III-IVa NPC were included in the present study, and randomly divided into experimental group (10 cases treated with IMRT + endostar) and control group (13 cases treated with IMRT + chemotherapy of cis-dichlorodiamineplatinum). Endostar was intravenously administered from the first day of IMRT. The patients received a total of 2 cycles (14 days each) separating by a 7-day interval.IMRT combined with endostar did not have significantly different recent efficacy compared with IMRT combined with chemotherapy. IMRT combined with endostar and IMRT combined with chemotherapy had 2-year overall survival (OS) rates of 100.0% and 69.6%, respectively, without significant difference between each other (χ = 1.446, P = .299). The 2-year local relapse-free survival (LRFS) of the 2 groups were 100.0% and 81.3%, respectively, without significant difference between each other (χ = 1.000, P = .317). The 2-year distant metastasis-free survival (DMFS) of the 2 groups were 100.0% and 73.5% (χ = 1.591, P = .207), respectively. The 2-year progression-free survival (PFS) of the 2 groups were 100.0% and 67.3% (χ = 2.164, P = .141), respectively. However, the cumulative survival curves of OS, LRFS, DMFS, and PFS were separated between the 2 groups. The result that IMRT combined with endostar did not have significantly different long-term efficacy than IMRT combined with chemotherapy probably due to limited case number and short follow-up time. IMRT combined with endostar resulted in significantly lower grades of leucopenia, nausea/vomiting, weight loss, and oral mucositis compared with IMRT combined with chemotherapy. The grades of late adverse reactions of IMRT combined with endostar were not different from those of IMRT combined with chemotherapy.The present study demonstrates that, compared with IMRT combined with chemotherapy, IMRT combined with endostar has similar efficacy in the treatment of locally advanced NPC, but significantly weaker acute adverse reactions, which improve the life quality of NPC patients.

Conflict of interest statement

Disclosures: All authors declare no financial competing interests.

The authors have no funding and no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Cumulative survival curves after treatment with IMRT combined with endostar compared with radiotherapy combined with chemotherapy. The follow-ups lasted for 27 to 38 months, with a median duration of 36 months. (A) OS curves; (B) LRFS curves; (C) DMFS curves; and (D) PFS curves of the 2 groups. DMFS = distant metastasis-free survival, IMRT = intensity-modulated radiotherapy, LRFS = local relapse-free survival, OS = overall survival, PFS = progression-free survival.

References

    1. Deng W, Li J, Yu J, et al. Epidemiological characteristics and trends of nasopharyngeal carcinoma deaths in Guangxi. J Appl Prevent Med 2011;17:73–6.
    1. Cooper JS, Lee H, Torrey M, et al. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experience. Int J Radiat Oncol Biol Phys 2000;47:861–6.
    1. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005;23:6966–75.
    1. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730–8.
    1. Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631–7.
    1. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038–44.
    1. Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010;102:1188–98.
    1. Lin JC, Liang WM, Jan JS, et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 2004;60:156–64.
    1. Kang M, Zhou P, Wei T. The new T staging system for nasopharyngeal carcinoma based on intensity modulated radiation therapy: results of a prospective multicentric clinical study. Int J Radiat Oncol Biol Phys 2016;96:E343.
    1. Zhao H, Zhu C, Gu L. Efficacy of three dimensional conformal radiotherapy and chemotherapy plus adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma. Chin J Radiat Oncol 2011;20:8–9.
    1. Kang M, Long J, Li G. A new staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results of a prospective multicentric clinical study. Oncotarget 2016;7:15252–61.
    1. Lee A, Tung SY, Chua DT. Final report of NPC-9901trial on therapeutic gain and late toxicities attributed to concurrent-adjuvant chemotherapy for T1-4N2-3M0 nasopharyngeal carcinoma. Eur J Cancer Suppl 2009;7:471.
    1. Lee A, Tung SY, Chan AT. Final report of NPC-9902 trial on therapeutic gain and late toxicities by concurrent-adjuvant chemotherapy and/or accelerated fractionation for T3-4N0-1M0 nasopharyngeal carcinoma. Eur J Cancer Suppl 2009;7:22.
    1. Lin S, Lu JJ, Han L, et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer 2010;10:39.
    1. Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004;22:2643–53.
    1. Guan Y, Li A, Xiao W, et al. The efficacy and safety of endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget 2015;6:33926–34.
    1. Ling Y, Yang Y, Lu N, et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007;361:79–84.
    1. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071–121.
    1. Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human naso-pharyngeal carcinoma models. PLoS One 2012;7:e34646.
    1. Sun Y, Wang JW, Liu Y, et al. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small lung cancer (NSCLC) patients. J Clin Oncol 2005;23:7138.
    1. Han B, Xiu Q, Wang H, et al. A multicenter, randomized,double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 2011;6:1104–9.
    1. Zhou JF, Bai CM, Wang YZ, et al. Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer:a pilot study. Chin Med J (Engl) 2011;124:4299–303.
    1. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996;2:167–8.
    1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.
    1. O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277–85.
    1. Wang J, Sun Y, Liu Y, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2005;8:283–90.
    1. Zhou J, Wang L, Xu X, et al. Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models. Oncol Lett 2012;4:976–80.
    1. Zeng D, Lin Y, Wang H, et al. Inhibitory effect of rh-endostatin on vasculogenic mimicry in nasopharyngeal cancer cell line HNE-1 in vitro. Chin Clin Oncol 2008;6:481–4.
    1. Wen QL, Meng MB, Yang B, et al. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 2009;100:1510–9.
    1. Yang Z, Du Y, Xie Y. Inhibition of nasopharyngeal carcinoma CNE-2 xenograft in nude mice by recombinant human endostatin combined with radiotherapy and analysis of its mechanism. Chin J Can Prevention Treatment 2012;4:259–62.
    1. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53:133–40.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다